Record Revenue Marks a Strong Start to 2026 for Exagen
Exagen Inc. (NASDAQ:XGN) just posted one of its strongest quarters to date, reporting record revenue of $17.3 million for the first quarter of 2026. This marks a 12% increase compared to the same quarter last year, driven in part by a 10% rise in AVISE CTD test volumes and an expanded average selling price (ASP) of $444 per test, up 6% year-over-year. With these gains, Exagen continues to cement its leadership in autoimmune diagnostics.
Cash Position Nearly Doubles Year-over-Year
Perhaps more eye-catching than top-line growth is Exagen's liquidity position: The company closed the quarter with $21.51 million in cash and equivalents—up 92% from $11.19 million a year ago. Management credits disciplined execution and careful revenue cycle management for exceeding internal forecasts. This robust cash buffer is particularly significant in the diagnostics industry, where lengthy reimbursement cycles are a perennial challenge.
| Key Metrics | Q1 2026 | Q1 2025 | % Change |
|---|---|---|---|
| Revenue ($M) | 17.31 | 15.50 | +12% |
| Gross Margin (%) | 59.0 | 58.9 | +0.1 |
| Operating Expenses ($M) | 13.62 | 12.49 | +9% |
| Net Loss ($M) | (3.97) | (3.75) | +6% |
| Adj. EBITDA Loss ($M) | (2.16) | (2.51) | -14% |
| Cash & Equivalents ($M) | 21.51 | 11.19 | +92% |
| AVISE CTD ASP ($) | 444 | 419 | +6% |
Adjusted EBITDA Narrows, but Net Loss Remains a Headwind
While Exagen made marked progress in trimming its adjusted EBITDA loss (now $2.16 million, a 14% improvement from last year), the company continues to post net losses—$3.97 million for the quarter, slightly higher than the $3.75 million net loss in Q1 2025. Gross margins held steady at 59%, reflecting a tight operational focus, yet ongoing investment in research, innovation, and market expansion are keeping the path to full profitability a work in progress.
Guidance Highlights Confidence, but Profitability Remains Elusive
Looking ahead, Exagen is guiding for full-year 2026 revenue between $70 million and $73 million, signaling management’s confidence in continued growth. The improved cash position and higher ASPs suggest the company is well positioned to fund its operations without diluting shareholders in the near term. However, investors will be watching quarterly earnings closely for signs that narrowing losses can one day flip to consistent profitability—a milestone that remains just out of reach for now.
Key Questions for Investors as XGN Presses Forward
For shareholders and analysts, the most pressing question is whether Exagen’s record revenue and strong liquidity can translate into true operating leverage. Can ongoing growth in AVISE CTD volume and pricing build a foundation for sustainable margin expansion? Will the company’s discipline with cash continue to shelter it from the need for outside financing?
For now, Exagen’s latest earnings snapshot offers grounds for cautious optimism—and plenty for investors to keep monitoring as the year progresses.
Contact Information:
If you have feedback or concerns about the content, please feel free to reach out to us via email at support@marketchameleon.com.
About the Publisher - Marketchameleon.com:
Marketchameleon is a comprehensive financial research and analysis website specializing in stock and options markets. We leverage extensive data, models, and analytics to provide valuable insights into these markets. Our primary goal is to assist traders in identifying potential market developments and assessing potential risks and rewards.
NOTE: Stock and option trading involves risk that may not be suitable for all investors. Examples contained within this report are simulated and may have limitations. Average returns and occurrences are calculated from snapshots of market mid-point prices and were not actually executed, so they do not reflect actual trades, fees, or execution costs. This report is for informational purposes only, and is not intended to be a recommendation to buy or sell any security. Neither Market Chameleon nor any other party makes warranties regarding results from its usage. Past performance does not guarantee future results. Please consult a financial advisor before executing any trades. You can read more about option risks and characteristics at theocc.com.
The information is provided for informational purposes only and should not be construed as investment advice. All stock price information is provided and transmitted as received from independent third-party data sources. The Information should only be used as a starting point for doing additional independent research in order to allow you to form your own opinion regarding investments and trading strategies. The Company does not guarantee the accuracy, completeness or timeliness of the Information.
Disclosure: This article was generated with the assistance of AI